TECHNOLOGY: COPRIMERS™
CHANGING THE FUTURE
CoPrimers™
CoPrimers™
The unique, proprietary structure of
The CoPrimer™ Binding Process
NO PRIMER DIMERS, NO OPTIMIZATION, REAL MULTIPLEXING
1.
Long PROBE quickly “anchors” bringing the short PRIMER into close proximity with the DNA target
2.
The DNA strands fold, allowing the CoDX™ short primer to bind
3.
When the polymerase extends, the capture (probe) is cleaved, releasing the fluorophore

One of the most important attributes of Co-Diagnostics’ CoPrimer technology is the virtual elimination of “primer-dimers,” the principal source of false positives in diagnostic testing. Primer-dimers are essentially the amplification of errors that can take place during the course of a molecular diagnostic test. These errors dramatically minimize the accuracy of the test and lead to false results and/or inaccurate diagnoses.
The importance of test accuracy cannot be overstated, particularly in a medical diagnostic situation. To be able to accurately diagnose a condition will allow for appropriate treatment protocols that can have a profound quality of life impact on a patient. Inaccurate testing for cancer or infectious diseases can be a life or death proposition. By virtually eliminating “primer-dimers” from molecular diagnostic testing,
The End Result of CoPrimer™ Cooperativity
A Revolutionary Improvement in the
Top Three Objectives of Molecular Diagnostics
1.
Increased
Specificity
2.
Sharper
Sensitivity
3.
Mega
Multiplexing
Creating 80% reduction in research, design and development costs
Patents no. 10,093,966 and 10,704,087, both titled “COOPERATIVE PRIMERS, PROBES, AND APPLICATIONS THEREOF,” cover the physical structure, applications, and method for synthesizing a nucleic acid molecule in the structure first developed by Dr. Satterfield in 2012. Co-Diagnostics owns all the intellectual property on which

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.
LATEST NEWS RELEASE
Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share
Salt Lake City, Utah – November 2, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that following the discovery of an incorrectly...
ARCHIVE

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
COMPANY
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.